SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, tied to concerns about supply-chain constraints and the sustainability of AI-related spending, drove attention to SOXL, whose 3x leverage magnifies sector moves. Traders are divided between calling the drop an oversold washout and buying for a rebound, and warning that the chip downturn could deepen and leveraged losses may grow.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 earnings beat and raised full-year outlook failed to prevent a sharp selloff, with traders pointing to negative cash flow and heavy capex amid high expectations and weakness in AI-linked stocks. Bulls view the drop as an overreaction to investment-driven cash burn, while skeptics remain concerned about valuation and cash conversion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff alongside AI infrastructure and neocloud peers is the dominant topic, with traders citing broad market weakness and fears that debt-funded data-center expansion may be overvalued. The community is split between calling the decline an oversold buying opportunity and warning that continued selling and fresh lows could mean more downside.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares sold off sharply after Phase 3 results for its personalized melanoma vaccine with Mercks Keytruda leaked ahead of their presentation. Traders largely framed the decline as a sell-the-news reaction after a steep run-up: the results were positive, but many argued they fell short of elevated expectations, while others called the selloff an overreaction.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a sharp tech and semiconductor selloff, as concerns that heavy AI investment may not deliver returnsand rising financing costsprompt scrutiny of mega-cap spending; elevated oil prices and geopolitical tensions add to inflation worries. Traders are divided between expecting further losses and viewing the pullback near a key support area as a buying opportunity, with volatile rebounds fueling debate.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias quarterly earnings beat was overshadowed by weaker free-cash-flow guidance, higher restructuring costs, and concerns that supply-chain cost inflation could pressure margins, driving a steep selloff. Traders are split between viewing the decline as an overreaction to strong AI and cloud demand and seeing cash generation and managements outlook as reasons for caution.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat guidance have drawn attention, but shares sold off despite the beat. Traders are debating whether the decline reflects broader weakness in AI-linked technology stocks and worries that storage earnings are near a cyclical peak, or an overreaction to robust demand and pricing trends.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is drawing attention for volatile price action and a recent rebound, with traders watching whether it can break key resistance and extend the move. Bullish calls for another leg higher are tempered by concerns about low volume, repeated pullbacks, and its tendency to lag broader crypto and meme-coin rallies.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

RYCEY is drawing attention after a sharp pullback from its recent highs, with traders debating whether the decline reflects profit-taking and broader market or sector selling, or concerns about higher jet-fuel costs and Middle East disruption. Many bullish traders say the companys fundamentals remain intact and point to buybacks, while others remain concerned about continued selling and aviation-sector pressures.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure as semiconductor stocks sell off on concerns that supply-chain constraints could limit chipmakers ability to meet demand, alongside worries about AI spending and financing. Traders are split between expecting further downside and viewing the sharp decline as an oversold dip that could stabilize or bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Turning Towards Momentum Narratives

Small-cap healthcare and emerging growth stocks continue to generate investor interest as multiple companies announced significant regulatory, scientific, and strategic developments. $NTHI, $ERNA, $VIVS, $LLY, $VEEE, $SOBR

Ernexa Scores Independent Validation Before High-Stakes Human Cancer Therapy Trials

Ernexa Therapeutics (NASDAQ:ERNA) has taken a notable step toward the clinic after announcing that an independent contract research organization successfully reproduced the preclinical efficacy of its lead cell therapy candidate, ERNA-101, in ovarian cancer models. Independent validation is closely watched in biotechnology because reproducibility can strengthen confidence in experimental findings before human testing begins.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million.
Catheter Precision (AMEX:VTAK)read more...

ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.

Chasing the Next Explosive Small-Cap Run

Risk appetite came roaring back and several companies standing out, as market participants rotated heavily into sectors tied to transformative technologies and high-growth macro trends. $TGNT, $QUCY, $AEHL, $TDIC, $WGRX, $ERNA, $SLS, $WHWK

Ernexa Stock Is Jumping Today: What's Going On?

Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are surging Tuesday after an investor segment and renewed focus on ERNA 101 in ovarian cancer.read more...

ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts 

Equity

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period.

Biotech’s Next Wave May Already be in Motion

The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, late-stage clinical wins, and platform technologies are converging to reshape both valuations and patient outcomes. From aggressive insider buying ahead of critical data to blockbuster Phase 3 readouts redefining entire therapeutic categories, the market is signaling that the next cycle of winners may already be taking shape. $NTHI, $ERNA, $LLY, $NVO, $REGN, $MRNA

ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results

Ernexa’s ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models.

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics, Inc. (NASDAQ:ERNA) shares are trading higher Wednesday after the company announced preclinical data showing its ERNA-101 cell therapy candidate achieved complete tumor clearance...

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Ernexa Therapeutics, Inc. engages in the research and development of cellular therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. Its pipeline includes ERNA-101 (Ovarian Cancer) and ERNA-201 (Rheumatoid Arthritis). The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Loss per share narrowed to $6.95 from a loss of $57.76 per share last year.</li><li>Last week, the firm said its therapy completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models.</li><li>CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug application in the third quarter of 2026</li></ul>Shares of Ernexa Therapeutics Inc. (ERNA) extended their explosive rally on Tuesday, soaring more than 90% as investors piled into the biotech stock following a sharp narrowing of first-quarter losses and growing optimism around its promising ovarian cancer cell therapy program.Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period. The company also posted a sharp improvement in loss per share, which narrowed to $6.95 from $57.76 a year earlier.Trading in <a href="https://stocktwits.com/symbol/ERNA">ERNA shares</a> was halted seven times after the opening bell, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nyse.com/trade/trading-halts">according</a> to NYSE data.<h2 class="st-heading-2">Retail Can’t Stop Talking About ERNA’s Ovarian Cancer Trial Results</h2>Retail sentiment for ERNA shares on Stocktwits remained in the ‘extremely bullish’ territory, while message volumes increased by around 280% over a 24-hour period. ERNA was also among the top trending tickers on the platform.One user said the stock is a “long-term” investment, citing the trial update.<stembedurl>https://stocktwits.com/Alchemisttt/message/653084994</stembedurl>Another user said they were ‘hyper bullish’ about the trial results, but would not rule out a stock offering.<stembedurl>https://stocktwits.com/splitsoup/message/653083994</stembedurl><h2 class="st-heading-2">ERNA To File NDA BY Q3</h2>Last week, Ernexa <a href="https://stocktwits.com/news-articles/markets/equity/erna-stock-surged-ernexa-ovarian-cancer-trial/cZQzOzNReOK">said</a> its ERNA-101 therapy, combined with PD-1 immunotherapy, completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models, using mice. The therapy also boosted cancer-fighting immune activity and reduced tumor burden.In a letter to shareholders on Monday, CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug (IND) application in the third quarter (Q3) of 2026 and plans to begin a Phase 1 human trial later in the year.The stock has rallied nearly 250% since the pre-clinical trial results were reported.The company implemented a 1-for-25 reverse stock split earlier this month.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rigl-stock-jumps-short-interest-surges-to-record-high-why-is-retail-eyeing-a-further-upside/cZXXhLJReiW">RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits Polls

$ERNA these 3 stocks $ERNA $SXTC $NUWE 
Ruined my life. I lost over 250k in past 4 years on those stocks. So much scam and I fell for it. Not sure how am I going to come back. Wish I have sold earlier invested into NVDA AMD or any tech stock. I lost my hard earned money and I feel for it everyday. Don’t be like me, avoid those 3 stocks from your life and including China stocks, they will ruin your life

Russell

$ERNA soon under 1, just watch. I see 90 cents bids, Sanjeev is looting money with both hands

$ERNA detailed a new virtual investor segment highlighting ERNA-101's path toward clinic.

Feed

News

Sentiment

Fundamentals

Info

ERNA Ernexa Therapeutics Inc.

Fundamentals

Latest ERNA News